The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 07, 2013
Filed:
Aug. 13, 2008
Jin Cheng, San Jose, CA (US);
Stephen Dugan, Berkeley, CA (US);
Gordon Stewart, San Francisco, CA (US);
Gina Zhang, Calabasas, CA (US);
Nancy Kirsten, Tucson, AZ (US);
Paul Consigny, San Jose, CA (US);
Christopher Feezor, San Jose, CA (US);
Gene Park, Santa Rosa, CA (US);
Wouter Roorda, Palo Alto, CA (US);
Syed F. A. Hossainy, Fremont, CA (US);
Jin Cheng, San Jose, CA (US);
Stephen Dugan, Berkeley, CA (US);
Gordon Stewart, San Francisco, CA (US);
Gina Zhang, Calabasas, CA (US);
Nancy Kirsten, Tucson, AZ (US);
Paul Consigny, San Jose, CA (US);
Christopher Feezor, San Jose, CA (US);
Gene Park, Santa Rosa, CA (US);
Wouter Roorda, Palo Alto, CA (US);
Syed F. A. Hossainy, Fremont, CA (US);
Abbot Cardiovascular Systems Inc., Santa Clara, CA (US);
Abstract
A drug-delivery system is provided including at least 100 μg of everolimus and clobetasol, such that the ratio of everolimus to clobetasol is at least 10:1 (w/w) or the amount of everolimus by weight is at least 10 times more than clobetasol. The system can be a stent. Also provided a method of treating restenosis or vulnerable plaque of a blood vessel, the method includes locally administering to a patient a first drug selected from a group consisting of rapamycin (sirolimus), Biolimus A9, deforolimus, AP23572, tacrolimus, temsirolimus, pimecrolimus, zotarolimus (ABT-578), 40-O-(2-hydroxy)ethylrapamycin (everolimus), 40-O-(3-hydroxy)propylrapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethylrapamycin, 40-O-tetrazolylrapamycin and 40-epi-(N1-tetrazolyl)rapamycin, and locally administering to a patient a second drug consisting of clobetasol, wherein the minimum amount of the first drug that is locally administered is 100 μg, and wherein the ratio of the first drug to the second drug is, for example, 10:1 to 100:1 (w/w).